These authors contributed equally to this work.
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura
Article first published online: 30 NOV 2006
British Journal of Haematology
Volume 136, Issue 2, pages 309–314, January 2007
How to Cite
Emmerich, F., Bal, G., Barakat, A., Milz, J., Mühle, C., Martinez-Gamboa, L., Dörner, T. and Salama, A. (2007), High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. British Journal of Haematology, 136: 309–314. doi: 10.1111/j.1365-2141.2006.06431.x
- Issue published online: 30 NOV 2006
- Article first published online: 30 NOV 2006
- Received 3 September 2006; accepted for publication 18 October 2006
- idiopathic thrombocytopenic purpura;
- B-cell activating factor;
- promoter polymorphisms
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder in which platelets are opsonised by autoantibodies and destroyed by macrophages. Therefore, ITP represents a prototype of a B-cell-mediated autoimmune disorder. B-cell activating factor (BAFF) is a member of the tumour necrosis factor family and an important regulator of B-cell development. BAFF levels were determined in serum samples from 53 patients with ITP. Serum BAFF levels in patients with an active ITP were increased when compared with the healthy control group (median 1620 pg/ml vs. 977 pg/ml; P < 0·001). Moreover, immunosuppressive treatment was associated with strongly suppressed BAFF levels (median 629 pg/ml; P < 0·01). In addition, a polymorphic site was detected in the BAFF promoter region (−871) that appeared to occur more frequently in ITP patients than in healthy persons. This promoter variant was associated with very high BAFF levels in ITP patients. Our data suggest that BAFF is an important pathogenetic factor in the development of ITP.